High Vista Strategies LLC Morphic Holding, Inc. Transaction History

High Vista Strategies LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$21.33 - $59.42 $219,208 - $610,659	10,277 New	10,277 $235,000
Q3 2022 Nov 14, 2022	SELL	$22.23 - $33.37 $258,512 - $388,059	-11,629 Reduced 39.78%	17,601 $498,000
Q2 2022 Aug 15, 2022	BUY	$19.74 - $43.01 $361,498 - $787,642	18,313 Added 167.75%	29,230 $634,000
Q1 2022 May 16, 2022	SELL	$36.25 - $52.02 $465,232 - $667,624	-12,834 Reduced 54.04%	10,917 $438,000
Q4 2021 Feb 14, 2022	BUY	$43.27 - $65.72 $147,377 - $223,842	3,406 Added 16.74%	23,751 $1.13 Million
Q3 2021 Nov 15, 2021	BUY	$53.61 - $67.5 $130,165 - $163,890	2,428 Added 13.55%	20,345 $1.15 Million
Q2 2021 Aug 16, 2021	BUY	$45.13 - $64.99 $808,594 - $1.16 Million	17,917 New	17,917 $1.03 Million

4.7M

Ticker MORF
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,477,100
Market Cap $2.19B
Description
Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, metabolic diseases, as well as fibrosis and cancer. Its lead product candidates are MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation that is in Phase 1 clinical ...

Get notified when there are updates to the investment portfolio of High Vista Strategies LLC, based on Form 13F filings with the SEC.

Stay updated on High Vista Strategies LLC with notifications on news.